Palbociclib (codenamed PD-0332991, trade name Ibrance) is a drug for the treatment of HR-positive and HER2-negative breast cancer developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of IBRANCE (palbociclib) brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the IBRANCE (palbociclib) capsules cost price in India.
The order for IBRANCE (palbociclib) will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
IBRANCE (palbociclib) capsules, for oral use.
Generic Name: palbociclib
Capsules: 125 mg, 100 mg, and 75 mg..
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand IBRANCE (palbociclib) on prescription and Import License in Patient's Name only.
For overseas patients, IBRANCE (palbociclib) can be made available in Send your enquiry to find IBRANCE (palbociclib) in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For IBRANCE (palbociclib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Palbociclib Approved by FDA for Treatment of Male Patients With HR+/HER2- Breast Cancer For More Details
FDA Approves Pfizer’s Ibrance in Men With Breast Cancer For More Details